The investigation note that most SARS-CoV neutralizing Abs  isolated to date target the SB domain and that several of them recognize the RBM and prevent receptor engagement. As the SARS-CoV-2 and SARS-CoV SB domains share  75% amino acid sequence identity, future work will be necessary to evaluate whether any of these Abs neutralize the newly emerged coronavirus.